海特生物 reported revenue of ¥0.23B for the period ended 2026-06-30, -18.0% year on year. Net income was ¥-0.08B, a -35.4% net margin on a 34.2% gross margin. The largest revenue line is 生物制药报告分部 at 42% of the total. Free cash flow for the period was ¥-0.01B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.23B | -18.0% |
| Gross profit | ¥0.08B | — |
| Operating income | ¥-0.08B | — |
| Net income | ¥-0.08B | — |
| Gross margin | 34.2% | Net margin -35.4% |
| Revenue Q/Q | -58.2% | — |
| Segment | Revenue | Share |
|---|---|---|
| 生物制药报告分部 | ¥0.10B | 42.5% |
| 医药技术服务报告分部 | ¥0.09B | 41.2% |
| 医药中间体生产销售分部 | ¥0.03B | 15.5% |
| 体外诊断试剂分部 | ¥0.00B | 0.7% |
| 其他分部 | ¥0.00B | 0.1% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.15B | 65.8% |
| R&D | ¥0.04B | 17.5% |
| SG&A | ¥0.12B | 51.8% |
| Tax & other | ¥-0.00B | -1.4% |
| Item | Amount |
|---|---|
| Total assets | ¥2.47B |
| Total liabilities | ¥0.38B |
| Shareholders' equity | ¥2.09B |
| Equity / assets | 84.6% |
| Operating cash flow | ¥-0.00B |
| Capital expenditure | ¥0.01B |
| Free cash flow | ¥-0.01B |
| Cash conversion (OCF / net income) | 4% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
中石科技 ・ 艾德生物 ・ 智动力 ・ 赛意信息 ・ 创业黑马 ・ 澄天伟业 ・ 双一科技 ・ 联合光电 ・ 中赋科技 ・ 盛弘股份 ・ 蠡湖股份 ・ 兆丰股份
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies